Insider Transactions in Q1 2023 at Enanta Pharmaceuticals Inc (ENTA)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2023
|
Terry Vance Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,800
+21.57%
|
$81,200
$14.0 P/Share
|
|
Mar 15
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
10,440
-4.84%
|
$459,360
$44.2 P/Share
|
|
Mar 15
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,440
+8.81%
|
$146,160
$14.0 P/Share
|
|
Mar 15
2023
|
Yat Sun Or Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
13,925
-1.79%
|
$612,700
$44.19 P/Share
|
|
Mar 15
2023
|
Yat Sun Or Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,925
+3.46%
|
$194,950
$14.0 P/Share
|
|
Mar 13
2023
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
27,912
-1.11%
|
$1,256,040
$45.42 P/Share
|
|
Mar 13
2023
|
Jay R. Luly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,912
+3.19%
|
$390,768
$14.0 P/Share
|
|
Feb 13
2023
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,416
-13.94%
|
$333,632
$52.77 P/Share
|
|
Feb 13
2023
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,305
+20.15%
|
-
|
|
Feb 13
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,735
-8.41%
|
$350,220
$52.77 P/Share
|
|
Feb 13
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,997
+12.36%
|
-
|
|
Feb 13
2023
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,725
-14.35%
|
$349,700
$52.77 P/Share
|
|
Feb 13
2023
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,997
+20.45%
|
-
|
|
Feb 13
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,904
-6.61%
|
$359,008
$52.77 P/Share
|
|
Feb 13
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,997
+9.59%
|
-
|
|
Feb 13
2023
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,752
-2.03%
|
$403,104
$52.77 P/Share
|
|
Feb 13
2023
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,267
+3.0%
|
-
|
|
Feb 13
2023
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,591
-2.51%
|
$1,070,732
$52.77 P/Share
|
|
Feb 13
2023
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,505
+1.9%
|
-
|
|
Feb 09
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.85%
|
$270,000
$54.03 P/Share
|
|
Jan 09
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+3.08%
|
$39,368
$14.18 P/Share
|